Curing HCV in Incarcerated Patients (CHIP)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03018353|
Recruitment Status : Unknown
Verified May 2017 by Lisa Pratt, MD, San Francisco Department of Public Health.
Recruitment status was: Enrolling by invitation
First Posted : January 12, 2017
Last Update Posted : June 1, 2017
|Condition or disease||Intervention/treatment||Phase|
|Hepatitis C, Chronic||Drug: Patients receiving Sof/Vel (Epclusa) and Navigation services||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||100 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Curing HCV in Incarcerated Patients|
|Actual Study Start Date :||March 5, 2017|
|Estimated Primary Completion Date :||March 4, 2018|
|Estimated Study Completion Date :||June 4, 2018|
Navigation services with sof/vel therapy
This a single group demonstration project in which, patients are treated with the FDA-approved drug, Sofosbuvir/Velpatasvir (Epclusa). If a patients is released during their treatment regimen, they will receive patient navigation services to continue their care and treatment in the community.
Drug: Patients receiving Sof/Vel (Epclusa) and Navigation services
Implementing HCV treatment in the jails using FDA-approved medications and continuing there treatment in the community if they are released during their treatment regimen.
- SVR12 of 70% or greater [ Time Frame: 12 months ]The primary objective is to implement a feasible HCV treatment program in an urban jail setting, City & County of San Francisco, over a 12 month period, with demonstration of a SVR12 of 70% or greater among inmates who initiates HCV treatment
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03018353
|United States, California|
|Jail Health Services|
|San Francisco, California, United States, 94103|